The Company that Advised Itself

Last night as my plane leveled off at 30,000 ft I decided to get stuck into a glass of wine and the Biotech Daily. While flicking through the bioscience news de jour, I saw the following comment about IQ3 Group (ASX : IQ3): IQ3 says it has been appointed as corporate advisor to the Iqnovate agreement to…

Merckonomics

I have received a few snotty emails the last couple of days regarding my commentary about Bionomics (ASX : BNO). Fair enough. Yes, I accepted face-value information about chemical composition instead of trawling patents, and yes I am anal-retentive about “mechanism of action” details for CNS drugs. So shoot me. At least someone is asking questions. Amidst the…

No ImpediMed to Success

I’ll be the first to admit that is a terrible play on words, but it was the best I could come up with today. ImpediMed (ASX : IPD) is an interesting little company and there is a lot to like about it. The company’s basic technology is called bioelectrical impedance analysis (or bioimpedance analysis) and basically involves passing…

Nexvet : Looking after (wo)man’s best friend…

My name is Chris Behrenbruch, and I live with a cat named Kuzya. In case you have wondered why I started this post this way, I figured after taking a look at Nexvet’s management bios on the company website, I would lack credibility if I didn’t also disclose my relationship to the aforementioned moggy. To…

Cynata Therapeutics : The Flip Flop

I make no effort to hide the fact that Cynata (ASX : CYP) is one of the ASX-listed biotechnology companies that I despise the most. It is the worst example of a “hollow chocolate bunny” that will only ever deliver on wild speculation from retail punters wowed by the words “stem cells.” If, one day,…